Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME Study of Olomorasib in Healthy Adults
NCT05901311Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2023
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of olomorasib in non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and solid tumor (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Fraction of Dose Excreted in Urine, Cumulative Fraction of Dose Excreted in Urine and 4 more. Started Jun 2023; status: completed.
02
Drugs
olomorasib
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)solid tumor
Beyond the preview
Go deeper on NCT05901311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05901311.